MX2021012848A - Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. - Google Patents
Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.Info
- Publication number
- MX2021012848A MX2021012848A MX2021012848A MX2021012848A MX2021012848A MX 2021012848 A MX2021012848 A MX 2021012848A MX 2021012848 A MX2021012848 A MX 2021012848A MX 2021012848 A MX2021012848 A MX 2021012848A MX 2021012848 A MX2021012848 A MX 2021012848A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- crohn
- mirikizumab
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836910P | 2019-04-22 | 2019-04-22 | |
| PCT/US2020/028273 WO2020219314A1 (en) | 2019-04-22 | 2020-04-15 | Mirikizumab for use in a method of treating crohn's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012848A true MX2021012848A (es) | 2021-12-10 |
Family
ID=70554215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012848A MX2021012848A (es) | 2019-04-22 | 2020-04-15 | Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220040299A1 (enExample) |
| EP (1) | EP3958897A1 (enExample) |
| JP (3) | JP7297930B2 (enExample) |
| KR (2) | KR20250153865A (enExample) |
| CN (2) | CN119700968A (enExample) |
| AU (2) | AU2020263238C1 (enExample) |
| BR (1) | BR112021018930A2 (enExample) |
| CA (1) | CA3134587A1 (enExample) |
| EA (1) | EA202192532A1 (enExample) |
| IL (2) | IL286818B1 (enExample) |
| MA (1) | MA55756A (enExample) |
| MX (1) | MX2021012848A (enExample) |
| SG (1) | SG11202110619XA (enExample) |
| TW (2) | TWI850365B (enExample) |
| UA (1) | UA128657C2 (enExample) |
| WO (1) | WO2020219314A1 (enExample) |
| ZA (1) | ZA202108094B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI850365B (zh) * | 2019-04-22 | 2024-08-01 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
| KR20220066831A (ko) | 2020-11-16 | 2022-05-24 | 엔브이에이치코리아(주) | 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20140049B1 (ar) | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
| EP3693007A1 (en) | 2013-03-15 | 2020-08-12 | Amgen, Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| TWI811716B (zh) * | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
| AU2017312049A1 (en) * | 2016-08-19 | 2019-02-21 | Janssen Biotech, Inc. | Methods of treating Crohn's Disease with an anti-NKG2D antibody |
| KR20200037258A (ko) * | 2017-07-10 | 2020-04-08 | 람밤 메드-테크 엘티디. | 생물학적 약물로 치료받은 피험자에서 중화 항체 수준 평가용 분석법 및 맞춤 의료에서 이의 사용 |
| TWI850365B (zh) * | 2019-04-22 | 2024-08-01 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
-
2020
- 2020-04-14 TW TW109112447A patent/TWI850365B/zh active
- 2020-04-14 TW TW113124301A patent/TW202515610A/zh unknown
- 2020-04-15 UA UAA202105413A patent/UA128657C2/uk unknown
- 2020-04-15 WO PCT/US2020/028273 patent/WO2020219314A1/en not_active Ceased
- 2020-04-15 AU AU2020263238A patent/AU2020263238C1/en active Active
- 2020-04-15 JP JP2021562882A patent/JP7297930B2/ja active Active
- 2020-04-15 CN CN202411949868.6A patent/CN119700968A/zh active Pending
- 2020-04-15 MA MA055756A patent/MA55756A/fr unknown
- 2020-04-15 CN CN202080030747.5A patent/CN113677366A/zh active Pending
- 2020-04-15 MX MX2021012848A patent/MX2021012848A/es unknown
- 2020-04-15 KR KR1020257033226A patent/KR20250153865A/ko active Pending
- 2020-04-15 EA EA202192532A patent/EA202192532A1/ru unknown
- 2020-04-15 SG SG11202110619XA patent/SG11202110619XA/en unknown
- 2020-04-15 KR KR1020217034113A patent/KR102869852B1/ko active Active
- 2020-04-15 CA CA3134587A patent/CA3134587A1/en active Pending
- 2020-04-15 BR BR112021018930A patent/BR112021018930A2/pt unknown
- 2020-04-15 EP EP20724301.5A patent/EP3958897A1/en active Pending
-
2021
- 2021-09-29 IL IL286818A patent/IL286818B1/en unknown
- 2021-10-21 ZA ZA2021/08094A patent/ZA202108094B/en unknown
- 2021-10-21 US US17/507,414 patent/US20220040299A1/en active Pending
-
2023
- 2023-06-14 JP JP2023097427A patent/JP7761614B2/ja active Active
- 2023-11-13 AU AU2023265759A patent/AU2023265759A1/en active Pending
-
2025
- 2025-07-10 JP JP2025116307A patent/JP2025148449A/ja active Pending
- 2025-10-19 IL IL324048A patent/IL324048A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119700968A (zh) | 2025-03-28 |
| JP2022530397A (ja) | 2022-06-29 |
| JP7761614B2 (ja) | 2025-10-28 |
| AU2020263238C1 (en) | 2024-02-22 |
| KR20210142704A (ko) | 2021-11-25 |
| AU2023265759A1 (en) | 2023-12-07 |
| TW202103734A (zh) | 2021-02-01 |
| US20220040299A1 (en) | 2022-02-10 |
| BR112021018930A2 (pt) | 2022-01-18 |
| CA3134587A1 (en) | 2020-10-29 |
| UA128657C2 (uk) | 2024-09-18 |
| IL324048A (en) | 2025-12-01 |
| CN113677366A (zh) | 2021-11-19 |
| EP3958897A1 (en) | 2022-03-02 |
| WO2020219314A1 (en) | 2020-10-29 |
| JP7297930B2 (ja) | 2023-06-26 |
| EA202192532A1 (ru) | 2022-01-21 |
| AU2020263238A1 (en) | 2021-11-04 |
| ZA202108094B (en) | 2025-05-28 |
| NZ781127A (en) | 2025-06-27 |
| IL286818A (en) | 2021-10-31 |
| AU2020263238B2 (en) | 2023-08-17 |
| SG11202110619XA (en) | 2021-11-29 |
| TWI850365B (zh) | 2024-08-01 |
| JP2023116680A (ja) | 2023-08-22 |
| IL286818B1 (en) | 2025-11-01 |
| JP2025148449A (ja) | 2025-10-07 |
| KR102869852B1 (ko) | 2025-10-14 |
| KR20250153865A (ko) | 2025-10-27 |
| TW202515610A (zh) | 2025-04-16 |
| MA55756A (fr) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| CY1125963T1 (el) | Ρυθμιστες υποδοχεα ρ2χ3 και ρ2χ2/3 διαμινοπυριμιδινης για χρηση στη θεραπεια βηχα | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| EP4327866A3 (en) | Mirikizumab in the treatment of ulcerative colitis | |
| MX2021008268A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. | |
| EA202190708A1 (ru) | Модуляторы экспрессии pnpla3 | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| MX385589B (es) | RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. | |
| MX2021013631A (es) | Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis. | |
| MX2022011972A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| MX390157B (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| MX2023007405A (es) | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. | |
| EA201992431A1 (ru) | Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. | |
| MX2017009929A (es) | Composiciones y métodos para metabolismo muscular mejorado. | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| MX2021012848A (es) | Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. | |
| CL2021000531A1 (es) | Métodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| MX2017013879A (es) | Composiciones que comprenden anakinra. | |
| EA201990768A1 (ru) | Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов |